Amendments to the Claims

1.-79. (canceled)

87. (new) An ELR-CXC chemokine antagonist, comprising an amino acid sequence substantially equivalent to the amino acid sequence of SEQ ID NO:1.

88. (new) The ELR-CXC chemokine antagonist of claim 87, wherein amino acid 30 of SEQ ID NO:1 is Gly instead of Pro.

89. (new) The ELR-CXC chemokine antagonist of claim 87, wherein amino acid 10 of SEQ ID NO:1 is Ser instead of Thr.

90. (new) The ELR-CXC chemokine antagonist of claim 89, wherein amino acid 11 of SEQ ID NO:1 is Phe instead of His.

91. (new) A method for treating an ELR-CXC chemokine-mediated pathology in which an ELR-CXC chemokine binds to CXCR1 or CXCR2 receptors in a mammal, the method comprising administering to said mammal an effective amount of the ELR-CXC chemokine antagonist as recited in claim 87.

92. (new) The method of claim 91, wherein the pathology is selected from the group consisting of ischemia-reperfusion injury, acute respiratory distress syndrome, immune complex-type glomerulonephritis, bacterial pneumonia, and mastitis.

93. (new) The method of claim 91, wherein the pathology is acute respiratory distress syndrome.